Several other analysts have also recently commented on the stock. Analysts at Needham & Company downgraded shares of Seattle Genetics from a buy rating to a hold rating in a research note to investors on Wednesday. They now have a $25.00 price target on the stock. They noted that the move was a valuation call. Analysts at Credit Suisse initiated coverage on shares of Seattle Genetics in a research note to investors on Thursday, December 6th. They set an outperform rating on the stock.
Five investment analysts have rated the stock with a buy rating, seven have issued a hold rating, and three have given a sell rating to the company. The company presently has a consensus rating of hold and an average price target of $26.00.
Seattle Genetics traded down 1.51% on Wednesday, hitting $27.38. Seattle Genetics has a 52-week low of $17.09 and a 52-week high of $30.85. The stock’s 50-day moving average is currently $28.03. The company’s market cap is $3.267 billion.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.